Tyrosine kinase inhibitors for the intervention of major morbid events in myeloproliferative neoplasms:reports from the 57th American Society of Hematology annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 150-152,156, 2016.
Artigo
em Chinês
| WPRIM
| ID: wpr-603354
ABSTRACT
With the research progress of pathogenesis of JAK gene in myeloproliferative neoplasms (MPN), more tyrosine kinase inhibitors were developed. MPN quantify scoring system is used to determine the efficacy of tyrosine kinase inhibitors for MPN. The choice of tyrosine kinase inhibitors, tyrosine kinase for the relief of MPN symptom burden, etc, become the topics of the 57th American Society of Hematology (ASH) annual meeting.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS